Brief: Pharmaust Files Positive Clinical Data With FDA To Support Orphan Drug Designation Request
14/03/2024 01:27
March 14 (Reuters) - Pharmaust Ltd PAA.AX :
* FILES POSITIVE CLINICAL DATA WITH FDA TO SUPPORT ORPHAN
DRUG
DESIGNATION REQUEST
Further company coverage: PAA.AX
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Neurizon Therapeutics
See all newsAustralia's Neurizon jumps on potential for neurodegenerative drug approval
Brief: Neurizon Therapeutics' Ongoing Healey ALS Platform Trial Affirmed By FDA
Brief: Neurizon Therapeutics Says Dr Chris Bremer Commences As CEO
Brief: Neurizon Therapeutics Appoints Chris Bremer As Chief Executive Officer
Brief: Neurizon Therapeutics Enters Strategic Research And Development Financing Facility